13 November 2018
EMA/PDCO/724133/2018 Corr.[1]
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 16-19 October 2018

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

16 October 2018, 14:00- 19:00, room 3A

17 October 2018, 08:30- 19:00, room 3A

18 October 2018, 08:30- 19:00, room 3A

19 October 2018, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

[1] Correction under the point 6.1.1

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted and will be published on the EMA website.

1.3. Adoption of the minutes

The minutes of the September 2018 PDCO were adopted and will be published on the EMA website.

2. Opinions

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Janus Kinase-1 inhibitor - EMEA-002312-PIP01-17

Pfizer Ltd; Treatment of moderate to severe Atopic Dermatitis

Day 120 opinion

Dermatology

Summary of committee discussion:

The Committee considered all issues resolved. A deferral was granted
The PDCO adopted a positive opinion.

2.1.2. Ixekizumab - EMEA-001050-PIP02-18

Eli Lilly & Company Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) / Children with juvenile idiopathic arthritis subtypes of enthesitis-related arthritis (including JoAS) and juvenile psoriatic arthritis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

At their October 2018 meeting, the PDCO agreed a PIP for ixekizumab 'Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) - arising from the split of EMEA-001050-PIP01-10-M03 - with a deferral.

2.1.3. Cenicriviroc - EMEA-001999-PIP02-17

Allergan Pharmaceuticals International Limited; Treatment of NASH with Stage 2-3 fibrosis

Day 120 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The applicant's response to the Day 90 issues was acceptable and a positive opinion on this application was adopted.

2.1.4. Upadacitinib - EMEA-001741-PIP04-17

AbbVie Ltd; Treatment of Atopic Dermatitis

Day 120 opinion

Immunology-Rheumatology-Transplantation / Dermatology

Summary of committee discussion:

An Oral Explanation Meeting (OEM) with the applicant took place on 18 October 2018. The Committee granted a deferral.
The PDCO adopted a positive opinion.

2.1.5. Brincidofovir - Orphan - EMEA-001904-PIP02-17

Chimerix UK Limited; Treatment of AdV in immunocompromised patients

Day 120 opinion

Infectious Diseases

Summary of committee discussion:

All the issues discussed were considered adequately addressed by the applicant. Therefore, the Committee adopted a positive opinion.

2.1.6. Brincidofovir - Orphan - EMEA-001904-PIP03-18

Chimerix UK Limited; Treatment of smallpox

Day 120 opinion

Infectious Diseases

Summary of committee discussion:

After the evaluation of all submitted information and based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO adopted a positive opinion.

2.1.7. Eubacterial Spores, Purified Suspension, Encapsulated - EMEA-001970-PIP02-17

Seres Therapeutics UK Ltd.; Treatment of Clostridium difficile infection / Reduce recurrence of Clostridium difficile infection (CDI) in paediatric patients who have received antibacterial drug treatment for recurrent CDI

Day 120 opinion

Infectious Diseases

Summary of committee discussion:

PDCO discussed the responses submitted by the applicant at Day 90. PDCO considered that most of the responses were acceptable. The PDCO therefore adopted a favourable Opinion.

2.1.8. Evobrutinib - EMEA-002284-PIP01-17

Merck KGaA; Treatment of multiple sclerosis

Day 120 opinion

Neurology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's modified proposal for the PIP. A positive opinion was therefore adopted.

2.1.9. Brigatinib - EMEA-002296-PIP01-17

Takeda Pharm A/S; Inflammatory Myofibroblastic Tumors (IMT), Non-small cell lung cancer (NSCLC), Anaplastic large cell lymphoma (ALCL) / Treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC), Treatment of paediatric patients ≥1 years of age with ALK+ unresectable or recurrent IMT, Treatment in combination with standard chemotherapy in paediatric patients ≥1 years of age with newly diagnosed ALK+ ALCL at high risk for recurrence

Day 120 opinion

Oncology

Summary of committee discussion:

The application for brigatinib was re-discussed taken into account the comments received by the applicant. In conclusion, the PDCO recommended granting:
1) a paediatric investigation plan in the conditions 'treatment of anaplastic large cell lymphoma' and 'treatment of inflammatory myofibroblastic tumours',
2) a waiver for all subsets of the paediatric population from birth to less than 18 years of age in the condition 'treatment of non-small cell lung cancer'.

2.1.10. Calcifediol - EMEA-002093-PIP02-17

Vifor Fresenius Medical Care Renal Pharma France; Treatment of secondary hyperparathyroidism (SHPT) / Treatment of secondary hyperparathyroidism (SHPT) in non-dialysis chronic kidney disease (ND-CKD) patients with low serum 25-hydroxyvitamin D levels

Day 120 opinion

Uro-nephrology

Summary of committee discussion:

The Committee discussed the clarification provided by the applicant, which was found acceptable. As all other remaining issues were clarified a positive opinion was adopted.

2.1.11. Ezetimibe / atorvastatin - EMEA-002410-PIP01-18

QualipharmaCon Kft.; Treatment of hypercholesterolaemia

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for ezetimibe / atorvastatin for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of hypercholesterolaemia. The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.12. Flurpiridaz F18 - EMEA-002413-PIP01-18

GE Healthcare, Inc.; Coronary artery disease

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Flurpiridaz F18 for all subsets of the paediatric population (0 to 18 years of age) in the condition of Diagnosis of coronary artery disease.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.13. Sarilumab - EMEA-001045-PIP04-18

Sanofi-Aventis Recherche et Développement; Muscular auto-immune disorder

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for sarilumab for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition "Treatment of polymyalgia rheumatica".
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified *myasthenia gravis* and polymyositis as an unmet need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.14. Entacapone / carbidopa monohydrate / levodopa - EMEA-002421-PIP01-18

LobSor Pharmaceuticals AB; Treatment of Parkinson's disease and Parkinsonism

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for levodopa / entacapone / carbidopa monohydrate for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of Parkinson's disease and Parkinsonism.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.15. Alectinib hydrochloride - EMEA-002431-PIP01-18

Roche Registration GmbH; Treatment of non-small cell lung cancer

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed the requested product specific waiver for the 'Treatment of non-small cell lung cancer' taking into consideration the additional clarifications provided by the applicant after the Day 30 discussion.

On the basis of this additional information, the members considered it adequate to limit the scope of this application to 'treatment of non-small cell lung cancer' since although alectinib has the possible advantage of accumulating in the central nervous system compared to crizotinib and it is efficacious in some patients who have developed resistance to crizotinib, at this stage this does not seem to be essential for paediatric patients as resistance to crizotinib has not been reported up to date for this population.

In conclusion, based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver and recommends granting a waiver for alectinib (hydrochloride) for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of non-small cell lung cancer.

The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.16. Avadomide - Orphan - EMEA-002405-PIP01-18

Celgene Europe Limited; Treatment of mature B-cell neoplasms

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Avadomide for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of mature B-cell neoplasms.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.17. Crizotinib - EMEA-001493-PIP02-18

Pfizer Limited; Treatment of lung malignant neoplasms

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for crizotinib for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of lung malignant neoplasms.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified paediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumours as two areas of unmet need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.18. Ipatasertib - EMEA-002396-PIP01-18

Roche Registration GmbH; Treatment of prostate cancer, Treatment of breast cancer

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this procedure during the October 2018 plenary.
The applicant requests a product-specific waiver for the entire paediatric population for the conditions treatment of breast cancer and treatment of prostate cancer.
The PDCO considered the additional information provided by the applicant between Day 30 and Day 60. Although AKT is expressed in several paediatric tumours, the significance of such expression in relation to the tumour is unclear and very little data are available at this stage showing anti-tumour activity in paediatric malignancies as a single agent. The PDCO recommended that the applicant considers emerging data and, based on them, carries out studies in patients with relevant paediatric cancers.
It terms of the request for a waiver, the PDCO considered that the waiver for the treatment of breast cancer and for the treatment of prostate cancer is acceptable, given that both cancers are virtually non-existent in the paediatric population.
Taking the above into consideration, the PDCO adopted a positive opinion at Day 60.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for ipatasertib for all subsets of the paediatric population (0 to 18 years of age) in the conditions of 'Treatment of prostate cancer', 'Treatment of breast cancer'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric

population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.19. Molibresib - EMEA-002406-PIP01-18

GlaxoSmithKline Trading Services Limited; Malignant neoplasm of breast / Oestrogen receptor-positive breast cancer (ER+BC)

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO discussed this procedure during the October 2018 plenary.
This application is for a waiver for treatment of malignant neoplasm of the breast.
The PDCO considered the information provided on data available and on future development plans.
It terms of the request for a waiver, the PDCO considered that a waiver for the treatment of breast cancer could be acceptable, given that breast cancer is exceedingly rare in the paediatric population.
The PDCO discussed again the grounds for the waiver and considered that because breast cancer could be very rarely observed in the paediatric population, the waiver should be granted on the grounds of lack of significant therapeutic benefit as clinical studies are not feasible.
Taking the above into consideration, the PDCO adopted a positive opinion for a waiver for the treatment of breast cancer for this product and recommended that studies are carried out in paediatric patients with cancers against whom molibresib has shown strong activity (for example, neoroblastoma and DIPG).
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for molibresib for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of breast cancer.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified neuroblastoma and diffuse intrinsic pontine glioma as an unmet need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.20. Pemigatinib - EMEA-002370-PIP01-18

Incyte Biosciences Distribution B.V.; Treatment of urothelial carcinoma, Treatment of cholangiocarcinoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed the requested product specific waiver for pemigatinib for the 'treatment of cholangiocarcinoma' and 'treatment of urothelial carcinoma' taking into consideration the additional clarifications provided by the applicant after the Day 30 discussion.

On the basis of this additional information, it was considered adequate to limit the scope of this application to 'treatment of cholangiocarcinoma' and 'treatment of urothelial carcinoma'.

In conclusion, based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of 'treatment of cholangiocarcinoma' and 'treatment of urothelial carcinoma'.

The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.21. Selinexor - Orphan - EMEA-002387-PIP01-18

Karyopharm Europe GmbH; Relapse/ Refractory Multiple myeloma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this procedure during the October 2018 plenary. The PDCO assessed the additional information the PDCO asked at Day 30. Given that multiple myeloma hardly exists in children the PDCO agreed with granting a waiver for the treatment of multiple myeloma.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Selinexor for all subsets of the paediatric population (0 to 18 years of age) in the condition 'Treatment of multiple myeloma'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.22. Ibuprofen - EMEA-002400-PIP01-18

Medherant Ltd.; Short-term symptomatic treatment of pain

Day 60 opinion

Pain

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for ibuprofen for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of pain.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.23. Dapagliflozin - EMEA-000694-PIP04-18

AstraZeneca AB; N18 Chronic Kidney Disease

Day 60 opinion

Uro-nephrology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for dapagliflozin for all subsets of the paediatric population (0 to 18 years of age) in the condition of Chronic Kidney Disease.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Ranibizumab - EMEA-C-000527-PIP04-13-M01

Novartis Europharm Limited; Treatment of retinopathy of prematurity

Day 30 opinion

Ophthalmology

Summary of committee discussion:

The PDCO discussed the completed study and considered that it is compliant with the latest Agency's Decision P/0010/2017 of 31 January 2017.
The PDCO took note of preceding procedure EMEA-C1-000527-PIP04-13-M01 and report EMA/481741/2018 on partially completed compliance.

The PDCO adopted on 19 October 2018 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision

(P/0010/2017) of 31 January 2017.

2.2.2. Ceftaroline fosamil - EMEA-C-000769-PIP01-09-M08

Pfizer Limited; Treatment of complicated skin and soft tissue infections

Day 30 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO discussed the completed study and considered that it is compliant with the latest Agency's Decision (P/0176/2018) of 15 June 2018.
The PDCO took note of preceding procedures and reports on partially completed compliance:
-EMEA-C1-000769-PIP01-09-M04 (compliance report EMA/178405/2015),
-EMEA-C2-000769-PIP01-09-M08 (compliance report EMA/513946/2018).

The PDCO adopted on 19 October 2018 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision P/0176/2018 of 15 June 2018.

2.2.3. Metreleptin - EMEA-C2-001701-PIP01-14-M01

Aegerion Pharmaceuticals B.V.; Treatment of lipodystrophy

Day 30 letter

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO discussed the completed study and considered that it is compliant with the latest Agency's Decision (P/0314/2016) of 25 November 2016.

The PDCO finalised on 19 October 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.4. Depatuxizumab mafodotin - EMEA-C2-001732-PIP02-15

AbbVie Ltd; Treatment of high-grade glioma

Day 30 letter

Oncology

Summary of committee discussion:

The PDCO finalised on 19 October 2018 this partial compliance procedure.

2.2.5. Gemtuzumab Ozogamicin - EMEA-C2-001733-PIP02-15-M01

Pfizer Limited; Treatment of acute myeloid leukaemia

Day 30 letter

Oncology

Summary of committee discussion:

The PDCO discussed the completed study and considered that these are compliant with the latest Agency's Decision (P/0326/2017) of 31 October 2017.
The PDCO finalised on 19 October 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.6. Quizartinib - EMEA-C2-001821-PIP01-15-M02

Daiichi Sankyo Europe GmbH; Treatment of acute myeloid leukaemia

Day 30 letter

Oncology

Summary of committee discussion:

The PDCO finalised on 19 October 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Enalapril maleate - EMEA-001706-PIP01-14-M02

Ethicare GmbH; Treatment of heart failure

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Tadalafil - EMEA-000452-PIP02-10-M05

Eli Lilly and Company Ltd; Benign prostatic hyperplasia (already approved in adults), Pulmonary arterial hypertension (already approved in adults) / Treatment of Persistent Pulmonary Hypertension of the Newborn, Treatment of Pulmonary Arterial Hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0127/2016 of 20 May 2016).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.3. Dabigatran etexilate mesilate - EMEA-000081-PIP01-07-M11

Boehringer Ingelheim International GmbH; Treatment of thromboembolic events, Prevention of thomboembolic events / Treatment of venous thromboembolic events in paediatric patients (secondary venous thrombotic event prevention)

Day 60 opinion

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of committee discussion:

Based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0301/2017 of 6 October 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Edoxaban (tosylate) - EMEA-000788-PIP02-11-M08

Daiichi Sankyo Europe GmbH; Prevention of arterial thromboembolism, Prevention of venous thromboembolism, Treatment of venous thromboembolism / Prevention of arterial thromboembolism in paediatric cardiac patients at risk of thrombotic events, Acute treatment & secondary prevention of symptomatic recurrent venous thrombotic events (VTE) in paediatric patients at risk

Day 60 opinion

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of committee discussion:

The PDCO confirmed the outcome of the Day 30 discussion and based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the committee considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0141/2018 of 07/05/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Certolizumab pegol - EMEA-001071-PIP03-14-M01

UCB Pharma SA; Treatment of psoriasis / Moderate to severe chronic plaque psoriasis

Day 60 opinion

Dermatology

Summary of committee discussion:

Based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed request to convert this PIP to a full product specific waiver on the grounds of lack of significant benefit over existing treatments is acceptable.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0101/2016 of 15 April 2016).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.6. Lixisenatide - EMEA-000916-PIP01-10-M06

sanofi-aventis R&D; Treatment of type 2 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0133/2016 of 20/05/2016).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Tolvaptan - EMEA-001231-PIP02-13-M06

Otsuka Pharmaceutical Europe Ltd.; Polycystic Kidney Disease (PKD) / Treatment of progression of ADPKD, Treatment of progression of ARPKD

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism / Uro-nephrology

Summary of committee discussion:

Based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0347/2017 of 01/12/2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.8. Apremilast - EMEA-000715-PIP05-13-M03

Celgene Europe Limited; Treatment of Behçet's Disease / Treatment of oral ulcers associated with Behçet's Disease in children and adolescents from the age of 6 to less than

18 years

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO's view expressed at Day 30 was re-discussed and endorsed. The applicant provided clarification, which was found acceptable by the Committee.
A positive opinion was adopted at Day 60.

2.3.9. Autologous CD34+ haematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene - Orphan - EMEA-001974-PIP01-16-M02

Orchard Therapeutics Limited; Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO re-discussed this procedure during the October 2018 plenary.
The PDCO considered the changes proposed by the applicant between Day 30 and Day 60. In conclusion, the PDCO adopted a positive opinion at Day 60. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0331/2017 of 31/10/2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Filgotinib - EMEA-001619-PIP04-17-M01

Gilead Sciences International Ltd.; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis, and juvenile idiopathic arthritis) / Treatment of juvenile idiopathic arthritis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO confirmed the outcome of the Day 30 discussion. Based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the committee considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0273/2017 of 04/10/2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.11. Ixekizumab - EMEA-001050-PIP01-10-M04

Eli Lilly & Company Limited; Plaque psoriasis / Treatment of psoriasis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the review of the rationale submitted in the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The current PIP will maintain only the condition 'Treatment of Psoriasis'.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0011/2018 of 30/1/2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.12. Secukinumab - EMEA-000380-PIP02-09-M04

Novartis Europharm Limited; Chronic Idiopathic Arthritis / Treatment of juvenile psoriatic arthritis, Treatment of enthesitis-related arthritis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO confirmed the outcome of the Day 30 discussion and based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the committee considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0168/2016 of 17/06/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Avibactam / ceftazidime - EMEA-001313-PIP01-12-M08

Pfizer Limited; Treatment of bacterial infections / Treatment of complicated urinary tract infections, Treatment of complicated intra-abdominal infections, Treatment of pneumonia, Treatment of infections due to aerobic Gram-negative organisms

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0149/2018 of 17/05/2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.14. Letermovir - Orphan - EMEA-001631-PIP01-14-M03

Merck Sharp & Dohme (Europe), Inc.; Prevention of cytomegalovirus infection / Prevention of CMV viremia and/or disease in at-risk patients having undergone an allogeneic HSCT or SOT

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted.
The PDCO re-discussed the requested modification also taking into account the additional information provided by the applicant.

The PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0090/2017 of 11 April 2017.

2.3.15. Amikacin sulfate - Orphan - EMEA-000525-PIP01-08-M06

Insmed Limited; Treatment of Pseudomonas aeruginosa lung infection/colonisation in cystic fibrosis patients, Treatment of nontubercolous mycobacterial (NTM) lung infection

Day 60 opinion

Infectious Diseases / Pneumology - Allergology

Summary of committee discussion:

The PDCO's views expressed on day 30 were re-discussed and endorsed.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0030/2015 of 30 January 2015).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.16. Nanobody directed towards the fusion protein of human respiratory syncytial virus - EMEA-001553-PIP01-13-M02

Ablynx NV; Treatment of RSV lower respiratory tract infection

Day 60 opinion

Neonatology - Paediatric Intensive Care

Summary of committee discussion:

The PDCO views expressed on day 30 were re-discussed taking into account the applicant's additional clarifications.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that only some of the proposed changes

could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0022/2017 of 30 January 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.17. D-sorbitol / naltrexone HCl / (RS)-bacoflen - Orphan - EMEA-002164-PIP01-17-M01

Pharnext SA; Charcot-Marie-Tooth disease Type 1A / Treatment of Charcot-Marie-Tooth Type 1A in symptomatic paediatric patients

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.18. Eculizumab - Orphan - EMEA-000876-PIP03-14-M02

Alexion Europe SAS; Neuromyelitis optica spectrum disorders / Treatment of paediatric patients with relapsing neuromyelitis optica spectrum disorders

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0375/2017 of 1 December 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.19. Lasmiditan - EMEA-002166-PIP01-17-M01

Eli Lilly and Company Limited; Treatment of migraine with and without aura

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed

paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (EMEA-002166-PIP01-17 of 15/6/2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.20. Risdiplam - EMEA-002070-PIP01-16-M02

Roche Registration GmbH; Treatment of spinal muscular atrophy

Day 60 opinion

Neurology

Summary of committee discussion:

During its plenary on 19 October 2018 the PDCO discussed the applicant's responses to the issues from Day 30 for the modification procedure for risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier, for treatment of spinal muscular atrophy (SMA).

The PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0080/2018 of 16/03/18).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.21. Daunorubicin (liposomal formulation) / cytarabine (liposomal formulation) - Orphan - EMEA-001858-PIP02-16-M02

JAZZ PHARMACEUTICALS IRELAND LIMITED; Treatment of acute myeloid leukaemia

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed the modification request for the liposomal combination of cytarabine and daunorubicin taking into account the clarifications provided by the applicant after the Day 30 discussion. In summary, all the issues were considered solved and the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0299/2017 of 04 October 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.22. Idasanutlin - Orphan - EMEA-001489-PIP01-13-M01

Roche Registration GmbH; Treatment of acute myeloid leukaemia, Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue), Treatment of acute lymphoblastic leukaemia / Treatment of children with first relapse of, or with frontline-refractory acute myeloid leukaemia, Treatment of children with first relapse of, or with frontline-refractory acute lymphoblastic leukaemia, Treatment of children with a solid malignant tumour which is

newly-diagnosed and metastatic, or refractory to first-line treatment

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO discussed this request for modification again in line with the additional information received between Day 30 and Day 60.
Overall, based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0285/2014).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.23. Idelalisib - EMEA-001350-PIP02-13-M04

Gilead Sciences International Ltd; Treatment of mature B-cell neoplasm / Treatment of children from 1 year to less than 18 years of age with a relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mediastinal B-cell lymphoma (MBCL) or Burkitt lymphoma

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver as part of this modification following the assessment of the additional information received during D30 and D60. The PDCO recommends granting a waiver for idelalisib for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of mature B-cell neoplasm, based on the lack of safety.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0018/2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.24. Ixazomib - Orphan - EMEA-001410-PIP02-17-M01

Takeda Pharm A/S; Treatment of Acute Lymphoblastic Leukaemia (ALL), Treatment of Multiple Myeloma (MM) / Treatment of adult patients with Newly Diagnosed Multiple

Myeloma (NDMM), Treatment of paediatric patients diagnosed with relapsed precursor B-ALL or T-ALL

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP. The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.25. Lenvatinib - Orphan - EMEA-001119-PIP02-12-M04

Eisai Europe Ltd; Treatment of papillary thyroid carcinoma, Treatment of Osteosarcoma, Treatment of follicular thyroid carcinoma / Treatment of refractory or relapsed osteosarcoma in children and adolescents, Treatment of progressive, radioiodine-refractory differentiated thyroid cancer in children and adolescents

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed the modification request taking into account the information provided by the applicant after the Day 30 discussion. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0107/2017 of 11 April 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.26. Dexamethasone / povidone-iodine - EMEA-001936-PIP01-16-M01

Shire Pharmaceuticals Ireland Ltd; Treatment of Infectious conjunctivitis (adenoviral and bacterial)

Day 60 opinion

Ophthalmology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0313/2016 of 21/12/2016).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.27. Ex vivo expanded autologous human corneal epithelium cells containing stem cells - Orphan - EMEA-001082-PIP02-11-M02

Chiesi Farmaceutici S.p.A.; Limbal stem cell deficiency due to ocular burns

Day 60 opinion

Ophthalmology

Summary of committee discussion:

The PDCO discussed this modification procedure on Day 60 and the applicant's responses to the issues raised on Day 30 were acknowledged.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0248/2015 of 30 October 2015).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.28. Ketorolac trometamol / phenylephrine hydrochloride - EMEA-001256-PIP02-12-M02

Omeros Corporation; Lens therapeutic procedure

Day 60 opinion

Ophthalmology

Summary of committee discussion:

Between Day 30 and Day 60 the applicant submitted information regarding the literature search as well as references.
The PDCO confirmed the outcome of the Day 30 discussion and -based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0136/2013 of 14/06/2013).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.29. Conestat alfa - EMEA-000367-PIP01-08-M08

Pharming Group N.V.; D84.1 Defects in the complement system esterase inhibitor (C1-INH) deficiency / Treatment of acute attacks of angioedema associated with hereditary C1 esterase inhibitor deficiency

Day 60 opinion

Other

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be

accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0016/2018 of 30 January 2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.30. Ivacaftor - Orphan - EMEA-000335-PIP01-08-M13

Vertex Pharmaceuticals (Europe) Limited; Treatment of Cystic Fibrosis

Day 60 opinion

Other

Summary of committee discussion:

The committee's views expressed on Day 30 were re-discussed. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0045/2018 of 16 February 2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.31. Palonosetron / fosnetupitant - EMEA-001198-PIP03-17-M01

Helsinn Birex Pharmaceuticals Limited; Prevention of chemotherapy-induced nausea and vomiting

Day 60 opinion

Other

Summary of committee discussion:

The committee's views expressed on Day 30 were re-discussed and endorsed. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0140/2018 of 07/05/2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.32. Peanut flour - EMEA-001734-PIP01-14-M03

Aimmune Therapeutics Inc; Peanut Allergy / Peanut oral immunotherapy for the reduction in clinical reactivity to accidental exposure in peanut children and adults

Day 60 opinion

Pneumology – Allergology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be

accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0170/2018 of 15 June 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.33. Tezepelumab - EMEA-001613-PIP01-14-M02

AstraZeneca AB; Treatment of asthma / Tezepelumab is indicated as add-on maintenance treatment of patients with severe asthma aged 5 years and older.

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0316/2014 of 5 December 2014).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.34. Potassium hydrogen carbonate / potassium citrate monohydrated - Orphan - EMEA-001357-PIP01-12-M02

Advicenne Pharma; Treatment of renal tubular acidosis

Day 60 opinion

Uro-nephrology

Summary of committee discussion:

No further information was provided after D30; however, based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO still considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.35. Cholera vaccine, live attenuated, oral (Strain CVD 103-HgR) - EMEA-001490-PIP01-13-M01

PaxVax Netherlands B.V.; Prevention of disease caused by V. cholerae serogroup O1

Day 60 opinion

Vaccines

Summary of committee discussion:

The PDCO considered the applicant's response after Day 30 satisfactory. The PDCO adopted

a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0286/2014 of 28 October 2014).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.36. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) - EMEA-001715-PIP01-14-M01

Seqirus Netherlands B.V.; Prevention of influenza

Day 60 opinion

Vaccines

Summary of committee discussion:

The PDCO's view expressed at Day 30 was endorsed. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0172/2016 of 17/06/2016).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.37. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) - EMEA-002068-PIP01-16-M02

Seqirus UK Limited; Prevention of influenza

Day 60 opinion

Vaccines

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the majority of the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision.
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.38. Pneumococcal Polysaccharide Serotype 33F – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 23F – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 22F – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 19F – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 19A – Diphtheria CRM197 Conjugate /

Pneumococcal Polysaccharide Serotype 18C – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 14 – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 9V – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 7F – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 6B – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 6A – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 5 – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 4 – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 3 – Diphtheria CRM197 Conjugate / Pneumococcal Polysaccharide Serotype 1 – Diphtheria CRM197 Conjugate - EMEA-002215-PIP01-17-M01

Merck Sharp & Dohme (Europe), Inc.; Prevention of disease caused by Streptococcus pneumoniae / Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age

Day 60 opinion

Vaccines

Summary of committee discussion:

Based on the additional information provided by the applicant between Day 30 and Day 60, the proposed modifications were considered acceptable and were implemented in the opinion.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP. The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.4. Opinions on Re-examinations

2.4.1. Peanut allergen extract - EMEA-001481-PIP01-13-M03

DBV Technologies S.A; peanut allergy

The opinion concerning the re-examination procedure was adopted via written procedure ending on 31 October 2018.

Pneumology - Allergology

2.5. Opinions on Review of Granted Waivers

No items

2.6. Finalisation and adoption of opinions

No items

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks, no need to refer them to PDCO Committee for discussion, were identified by the PME coordinator and PDCO Rapporteur. The PDCO has been informed in writing.

2.7.1. Fenfluramine hydrochloride - EMEA-C3-001990-PIP01-16-M01

Zogenix International Ltd; Treatment of Dravet syndrome

Day 30 letter

Neurology

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Evinacumab - EMEA-002298-PIP01-17

Treatment of elevated cholesterol / Treatment of homozygous familial hypercholesterolemia (HoFH)

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.2. Semaglutide - EMEA-001441-PIP03-17

Treatment of obesity

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.3. Ibrutinib - Orphan - EMEA-001397-PIP04-17

Janssen-Cilag International N.V.; Treatment of cGVHD / Treatment of cGVHD in children 1 year of age and older

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.4. Rezafungin acetate - EMEA-002319-PIP01-17

Treatment of invasive candidiasis

Day 90 discussion

Infectious Diseases

3.1.5. Tedizolid phosphate - EMEA-001379-PIP03-17

Treatment of Gram-positive bacterial pneumonia

Day 90 discussion

Infectious Diseases

3.1.6. Bilastine - EMEA-000347-PIP02-16

Treatment of allergic conjunctivitis

Day 90 discussion

Ophthalmology

3.1.7. Bupivacaine - EMEA-000877-PIP03-17

Postsurgical analgesia

Day 90 discussion

Pain

3.1.8. Meloxicam / bupivacaine - EMEA-002246-PIP01-17

Acute Post-Operative Pain

Day 90 discussion

Pain / Anaesthesiology

3.1.9. Remimazolam (as besylate) - EMEA-001880-PIP01-18

Anaesthetic and allied procedures / ICU sedation, General anaesthesia, Procedural sedation

Day 60 discussion

Anaesthesiology

3.1.10. Glycopyrronium bromide - EMEA-002383-PIP01-18

Hyperhidrosis / Treatment of primary axillary hyperhidrosis

Day 60 discussion

Dermatology

3.1.11. Oxalobacter formigenes Strain HC-1 - Orphan - EMEA-000370-PIP02-18

OxThera AB; Treatment of Primary Hyperoxaluria

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism / Uro-nephrology

3.1.12. Dusquetide - EMEA-002306-PIP02-18

Treatment of Severe Oral Mucositis

Day 60 discussion

Gastroenterology-Hepatology

3.1.13. Adeno-associated viral vector serotype 5 containing a B domain deleted variant of human coagulation factor VIII gene - Orphan - EMEA-002427-PIP01-18

BioMarin International Limited; Treatment of patients with haemophilia A

Day 60 discussion

Haematology-Hemostaseology

3.1.14. Allogeneic CD34+ umbilical cord blood cells cultured ex vivo with Notch ligand Delta1 - Orphan - EMEA-002271-PIP01-17

Nohla Therapeutics, Inc.; Haematopoietic Stem Cell Transplantation (HSCT) / Patients with high risk haematologic malignancies undergoing myeloablative cord blood transplant (CBT)

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.15. Inolimomab - Orphan - EMEA-002372-PIP01-18

ElsaLys Biotech SA; Acute Graft versus Host Disease following heamatopoietic stem cell transplantation

Day 60 discussion

Immunology-Rheumatology-Transplantation / Oncology / Haematology-Hemostaseology

3.1.16. Ganaxolone - EMEA-002341-PIP01-18

Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder / Adjunctive treatment of seizures in paediatric patients aged 2 to < 18 years old with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Day 60 discussion

Neurology

3.1.17. Humanized IgG1 monoclonal antibody against GD2 (hu3F8) - EMEA-002346-PIP01-18

Treatment of neuroblastoma

Day 60 discussion

Oncology

3.1.18. Aflibercept - EMEA-000236-PIP05-18

Treatment of retinopathy of prematurity (ROP)

Day 60 discussion

Ophthalmology

3.1.19. lentiviral vector containing the human ABCA4 gene for treatment of Stargardt's disease - Orphan - EMEA-002407-PIP01-18

Genzyme Europe B.V.; Treatment of inherited retinal disorders

Day 60 discussion

Ophthalmology

3.1.20. A fully human, IgG2 mAb - EMEA-002433-PIP01-18

Asthma / Treatment of severe asthma in patients 6 year-olds and above as an add-on therapy of standard of care

Day 60 discussion

Pneumology - Allergology

3.1.21. Recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) / Recombinant Influenza Hemagglutinin-strain B (Victoria lineage) / Recombinant Influenza Hemagglutinin-strain A (H3N2 subtype) / Recombinant Influenza Hemagglutinin-strain A (H1N1 subtype) - EMEA-002418-PIP01-18

Prevention of influenza infection

Day 60 discussion

Vaccines

3.1.22. Synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues - Orphan - EMEA-002425-PIP01-18

Alnylam Netherlands BV; Transthyretin-mediated amyloidosis

Day 30 discussion

Cardiovascular Diseases / Neurology

3.1.23. Budesonide - EMEA-002417-PIP01-18

Eosinophilic oesophagitis

Day 30 discussion

Gastroenterology-Hepatology

3.1.24. Bimekizumab - EMEA-002189-PIP02-18

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis) / Treatment of JIA (enthesitis-related arthritis [ERA] and juvenile psoriatic arthritis [JPsA]) in patients from ≥2 years to <18 years of age.

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.25. Bruton's tyrosine kinase inhibitor - Orphan - EMEA-002438-PIP01-18

Principia Biopharma, Inc.; Treatment of Pemphigus

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.26. Synthetic 47-amino-acid N-myristoylated lipopeptide - Orphan - EMEA-002399-PIP01-18

MYR GmbH; Chronic hepatitis D infection

Day 30 discussion

Infectious Diseases

3.1.27. Anti-VEGF and anti-DLL4 dual variable domain immunoglobulin - EMEA-002420-PIP01-18

Treatment of colorectal malignant neoplasms

Day 30 discussion

Oncology

3.1.28. Palbociclib - EMEA-002146-PIP02-18

Treatment of breast malignant neoplasms

Day 30 discussion

Oncology

3.1.29. Dexamethasone - EMEA-002423-PIP01-18

ICD10 H59.9 Postprocedural disorder of eye and adnexa, unspecified

Day 30 discussion

Ophthalmology

3.1.30. EMEA-002436-PIP01-18

Radiolabelling agent

Day 30 discussion

Other

3.1.31. (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid - Orphan - EMEA-002069-PIP03-17

Corbus Pharmaceuticals, Inc.; Treatment of Cystic Fibrosis

Day 30 discussion

Pneumology - Allergology

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Dupilumab - EMEA-C2-001501-PIP01-13-M05

Regeneron Pharmaceuticals, Inc., Treatment of atopic dermatitis

Day 30 discussion

Dermatology

3.2.2. Belimumab - EMEA-C-000520-PIP01-08-M05

Glaxo Group Limited; Treatment of systemic lupus erythematosus

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.2.3. Perampanel - EMEA-C5-000467-PIP01-08-M10

Eisai Europe Ltd; Treatment of treatment-resistant epilepsies

Day 30 discussion

Neurology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Rabeprazole sodium - EMEA-000055-PIP01-07-M06

Eisai Limited; E16.4 Abnormal secretion of gastrin: Zollinger-Ellison Syndrome, K26 Duodenal Ulcer, K25 Gastric Ulcer, B96.8 Helicobacter pylori in patients with peptic ulcer disease, K21.0 Gastro-oesophageal reflux disease / Treatment of symptomatic erosive or

ulcerative gastro-oesophageal reflux disease (GORD); symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic GORD), Treatment in combination with appropriate antibacterial therapeutic regimens for the eradication of helicobacter pylori in patients with peptic ulcer disease

Day 30 discussion

Gastroenterology-Hepatology

3.3.2. Bedaquiline (fumarate) - Orphan - EMEA-000912-PIP01-10-M04

Janssen-Cilag International NV; Treatment of multi-drug resistant tuberculosis

Day 30 discussion

Infectious Diseases

3.3.3. Ceftobiprole medocaril sodium - EMEA-000205-PIP02-11-M03

Basilea Pharmaceutica International Ltd.; J15: Bacterial pneumoniae not elsewhere classified, J13: Pneumonia due to Streptococcus pneumoniae, J14: Pneumonia due to Hemophilus influenzae / Treatment of nosocomial pneumonia, Treatment of community acquired pneumonia

Day 30 discussion

Infectious Diseases

3.3.4. Cobicistat / darunavir - EMEA-001280-PIP01-12-M02

Janssen-Cilag International NV; Treatment of HIV-1 infection / Treatment of HIV-1 infection in pediatric patients from 3 to less than 18 years

Day 30 discussion

Infectious Diseases

3.3.5. Dolutegravir (DTG) - EMEA-000409-PIP01-08-M05

ViiV Healthcare UK Ltd.; Treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.6. Pimodivir- EMEA-001975-PIP01-16-M02

Janssen-Cilag International NV; Treatment of influenza / To be used in combination with oseltamivir for the treatment of acute influenza A in adults and children < 18 years of age with complicated influenza or at high risk for complications

Day 30 discussion

Infectious Diseases

3.3.7. Lamivudine (3TC) / abacavir (ABC) / dolutegravir (DTG) - EMEA-001219-PIP01-11-M04

ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus (HIV-1) infection / Treatment Human Immunodeficiency Virus (HIV-1) infection in paediatric population

Day 30 discussion

Infectious Diseases

3.3.8. Fenfluramine hydrochloride - Orphan - EMEA-001990-PIP01-16-M02

Zogenix International Ltd; Dravet syndrome / The adjunctive treatment of seizures in paediatric patients at least 1 year of age with Dravet syndrome

Day 30 discussion

Neurology

3.3.9. Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 - Orphan - EMEA-001654-PIP01-14-M03

Novartis Europharm Limited; Treatment of B cell acute lymphoblastic leukaemia/lymphoblastic lymphoma / Treatment of CD19+ B cell acute lymphoblastic leukaemia (ALL) in paediatric patients whose disease is refractory to a standard chemotherapy regimen, relapsed after stem cell transplantation (SCT) or are ineligible for allogenic SCT

Day 30 discussion

Oncology

3.3.10. Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor - Orphan - EMEA-001862-PIP01-15-M01

Kite Pharma EU B.V.; Treatment of acute lymphoblastic leukaemia

Day 30 discussion

Oncology

3.3.11. Axicabtagene ciloleucel - Orphan - EMEA-002010-PIP01-16-M01

Kite Pharma EU B.V.; Treatment of mature B-cell neoplasms

Day 30 discussion

Oncology

3.3.12. Pazopanib EMEA-000601-PIP01-09-M05

Novartis Europharm Limited; Ewing sarcoma family of tumours, Rhabdomyosarcoma, Non-rhabdomyosarcoma soft tissue sarcoma / Treatment of pediatric patients with rhabdomyosarcoma, Treatment of pediatric patients with Ewing sarcoma family of tumours,

Treatment of pediatric patients with non-rhabdomyosarcoma soft tissue sarcoma

Day 30 discussion

Oncology

3.3.13. Ivacaftor / lumacaftor - EMEA-001582-PIP01-13-M08

Vertex Pharmaceuticals (Europe) Limited; treatment of cystic fibrosis

Day 30 discussion

Other

3.3.14. Sildenafil - Orphan - EMEA-000671-PIP01-09-M10

Pfizer Limited; Treatment of Pulmonary Arterial Hypertension (PAH)

Day 30 discussion

Other

4. Nominations

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 03 January 2019 for Nomination of Rapporteur and Peer reviewer

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

No items

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is

deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. Daromun EMEA-16-2018

Philogen S.p.A.; The class of immunomodulatory cytokine medicinal products for treatment of skin malignant neoplasms/Neoadjuvant treatment of fully resectable, clinical stage IIIB and IIIC cutaneous melanoma with injectable cutaneous, subcutaneous or nodal metastases

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: paediatric tumours with extra-domain B of fibronectin expressing tumour cells.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Fedratinib - EMEA-001325-PIP01-12

Celgene; Treatment of essential thrombocythaemia / Treatment of polycythaemia vera / Treatment of primary myelofibrosis

Proposed indication: Treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, including patients who have been previously exposed with ruxolitinib

Rapporteur: to be appointed

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

No items

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about the final CHMP Opinions on medicinal products with recommended paediatric indications adopted in September 2018. These included Jivi, Luxturna, Gilenya and RoActemra. A new strength (0.25 mg) of hard capsules of Gilenya was introduced to the currently approved presentations for use in paediatric patients from 10 years of age.

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in September 2018, was presented to the PDCO members.

9.2.2. Committee for Medicinal Products for Human Use (CHMP)

CHMP/PDCO joint session

Summary of committee discussion:

The topic discussed during the joint CHMP/PDCO session related to new medicines for treatment of haemophilia A and B

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The Chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The Chair of the Formulation Working Group identified the products which will require Formulation Working Group evaluation and discussion.

9.3.3. Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP)

Agenda PCWP meeting 25 Sep 2018

Agenda Joint PCWP/HCPWP meeting 25 Sep 2018

Agenda HCPWP meeting 26 Sep 2018

Summary of committee discussion:

The documents were tabled for information.

9.3.4. EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics

Summary of committee discussion:

The PDCO adopted the Reflection Paper on the use of extrapolation in the development of medicines for paediatrics.

9.3.5. Quality Working Party

9.3.5.1. Small Volume Q&A

Rapporteur: Diana van Riet

Summary of committee discussion:

An overview of the Q&A which has been integrated within the existing measuring devices QWP Q&A was presented. The rapporteur explained each section of the Q&A. The PDCO generally supported the recommendations outlined in the Q&A; however, requested that it should be clearly stated that insulin measuring devices are out of scope. The PDCO endorsed the Q&A with the additional sentence, which, after the PDCO plenary meeting was communicated to QWP and adopted by CHMP.

9.3.5.2. Enteral feeding tubes Q&A

Rapporteur: Abigail Moran

Summary of committee discussion:

An overview of the Q&A was presented and the rapporteur gave a detailed explanation of the content and background. The PDCO endorsed the Q&A without any comments. The Q&A was subsequently adopted by the CHMP.

9.4. Cooperation within the EU regulatory network

No items

9.5. Cooperation with International Regulators

No items

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No items

9.7. PDCO work plan

No items

9.8. Planning and reporting

No items

10. Any other business

10.1. AOB topic

10.1.1. Report from the FDA cluster TC

Summary of committee discussion:

The Committee was informed about the discussion topics at the October paediatric cluster tele-conference.

10.1.2. Summary of the Recommendations of the HMA-EMA Joint Big Data Taskforce

Summary of committee discussion:

The summary of the Recommendations of the HMA-EMA Joint Big Data Taskforce was presented to the Committee.

10.1.3. Concepts of significant benefit (follow-up to PDCO Work Plan 2017)

EMA presented current draft output of former PDCO work plan item on concepts of significant benefit.

10.1.4. ICH harmonised guideline on Nonclinical Safety Testing In Support Of Development Of Paediatric Medicines S11, draft version – Step 2

Rapporteur: Jan Willem van der Laan

The draft of ICH harmonised guideline on Nonclinical Safety Testing In Support Of Development of Paediatric Medicines S11 was presented to the Committee.

10.1.5. Report from the PDCO Strategic Review and Learning Meeting, 26 September – 28 September 2018, Vienna, Austria

PDCO member: Karl-Heinz Huemer

The report from the PDCO SRLM held in Vienna, Austria (26– 28 September 2018) was presented.

10.1.6. Business Pipeline quarterly update report

Summary of committee discussion:

The report was tabled for information.

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The group discussed some topics related to currently ongoing paediatric oncology procedures.

11.1.2. Neonatology

Summary of committee discussion:

The session was cancelled.

11.1.3. Inventory

Summary of committee discussion:

The paediatric inventory group convened on the margins of the PDCO plenary meeting to continue working on a methodology for the assessment of unmet needs.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the October 2018 meeting

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	No participation in final deliberations and voting on:	Molibresib - EMEA-002406-PIP01-18 and Belimumab - EMEA-C-000520-PIP01-08 -M05
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Adriana Andrić	Member	Croatia	No interests declared	
Suzana Mimica Matanovic	Alternate	Croatia	No interests declared	
Peter Szitanyi	Alternate	Czech Republic	No interests declared	
Kirstine Moll Harboe	Member	Denmark	No interests declared	
Mona Ring Gatke	Alternate	Denmark	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique	Alternate	France	No interests	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ploin			declared	
Sabine Scherer	Member	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Alessandro Jenkner	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Sigita Burokiene	Member	Lithuania	No interests declared	
Goda Vaitkeviciene	Alternate	Lithuania	No interests declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Maaike van Dartel (via TC)	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Marek Migdal	Member	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No interests declared	
Eva Agurell	Alternate	Sweden	No interests declared	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No interests declared	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals'	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
		Representative		
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Viviana Giannuzzi	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	
Catriona Elisabeth Baker	Expert - in person*	United Kingdom	No interests declared	
Jan Willem van der Laan	Expert - via telephone*	Netherlands	No interests declared	
Diana van Riet-Nales	Expert - via telephone*	Netherlands	No interests declared	
Abigail Moran	Expert - via telephone*	United Kingdom	No interests declared	
Homera Fahimeda Binte Ali	Expert - in person*	United Kingdom	No interests declared	
Kristin Karlsson	Expert - via telephone*	Sweden	No restrictions applicable to this meeting	
Jacqueline Kerr	Expert - via telephone*	Germany	No interests declared	
Anneliese Hilger	Expert - via telephone*	Germany	No interests declared	
Mirco Juergen Mueller Olling	Expert - via telephone*	Germany	No interests declared	
Shiva Ramroop	Expert - in person*	United Kingdom	No interests declared	
Juliana Min	Expert - in person*	United Kingdom	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ita Walsh	Expert - via telephone*	Netherlands	No interests declared	
Rune Kjeken	Expert - via telephone*	Norway	No restrictions applicable to this meeting	

* Experts were only evaluated against the agenda topics or activities they participated in

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/